arrow
D

David Price

University of British Columbia
H指数:106
被引数:4.9万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Association of Easier Biologic Access with Remission and Other Clinical Outcomes in Severe Asthma: A Global Real-World Study

易得生物制剂与重症哮喘缓解及其他临床结局的关联:一项全球真实世界研究

2026-08-060
OA
Chronic obstructive pulmonary disease and risk of incident cardiovascular disease, chronic kidney disease, and death: a systematic review and meta-analysis

慢性阻塞性肺疾病与心血管疾病、慢性肾脏疾病发病风险及死亡风险:一项系统评价和荟萃分析

2026-08-012
OAAI
Investigating differences in the implementation and experience of the Enhanced Health in Care Homes Framework in England: a qualitative protocol for the Understanding Variation in Admissions from Care Homes (UVAC) study

调查英格兰护理机构中“增强型护理机构健康框架”的实施与体验差异:一项理解护理机构入住变异(UVAC)研究的定性研究方案

2026-05-280
PRE
Identifying predictors and measuring variation in hospitalisation for older adult care home residents: a retrospective cohort study using routinely collected data

识别预测因子并测量老年护理机构住院治疗的变异:一项使用常规收集数据的回顾性队列研究

2026-05-010
PRE
Severe Asthma Patients’ Characteristics in Mexico Versus International Severe Asthma Registry (ISAR) Global

墨西哥与全球严重哮喘登记处(ISAR)严重哮喘患者特征比较

2026-03-190
PRE
Effect of budesonide/glycopyrronium/formoterol fumarate dihydrate on cardiopulmonary outcomes in COPD: rationale and design of the THARROS trial

布地奈德/格隆溴铵/富马酸福莫特罗二水合物对COPD患者心肺结局的影响: THARROS试验的原理和设计

2025-12-221
PRE
A 21-Practice Evaluation of an Asthma and COPD Quality Improvement Program

哮喘和COPD质量改进项目的21年实践评估

2025-11-110
OAAI
Correction to: The Association Between Short-Acting β2-Agonist Over-Prescription, and Patient-Reported Acquisition and Use on Asthma Control and Exacerbations: Data from Australia

更正:短效β2-激动剂过度处方与患者报告的获取和使用对哮喘控制及恶化的关联:澳大利亚数据

2025-09-260
OAAI
Changes in use and utilisation patterns of drugs with reported shortages between 2010 and 2024 in Europe and North America: a network cohort study

2010年至2024年欧洲和北美洲报告短缺药物的用药及利用模式变化:一项网络队列研究

2025-09-220
PREAI
Response to biologics along a gradient of T2 involvement in patients with severe asthma: a data-driven biomarker clustering approach

对重度哮喘患者T2炎症程度梯度下生物制剂应答的研究:一种数据驱动的生物标志物聚类方法

2025-09-020
OAAI
Prediction Pathway for Severe Asthma Exacerbations

严重哮喘急性发作的预测通路

CHEST
IF8.6
2025-05-190
OA
Patterns of care in the management of high-risk COPD in Australia (2015-2019): an observational study for the CONQUEST quality improvement program

澳大利亚高风险COPD的管理护理模式(2015-2019年):CONQUEST质量改进计划的观察性研究

2025-05-010
OA
CodeX effectively identifies high-risk patients with asthma or COPD in Dutch primary care, supporting guideline-driven treatment

CodeX能够有效识别荷兰初级保健中患有哮喘或COPD的高风险患者,支持基于指南的治疗。

2025-04-300
OA
Impact of Biologics Initiation on Oral Corticosteroid Use in the International Severe Asthma Registry and the Optimum Patient Care Research Database: A Pooled Analysis of Real-World Data

生物制剂启动对口服糖皮质激素使用的影响:国际重症哮喘注册登记研究与国际患者护理研究数据库的真实世界数据合并分析

2025-04-260
OAAI